//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon
EmailPrint

Registration

Online Registration is Open!
Register by Friday, February 27 to Save Up to $500 & Attend the Tuesday night evening networking reception for Free! (a $125 value)!

Download Brochure

Add to Outlook Calendar

Find Another IBC Event

Next Generation Protein Therapeutics

CSS

Cross-Fertilize Ideas from Multiple Disciplines and Turn Promising New Molecules into Differentiated Products

May 18-20, 2015 | Parc 55 Wyndham | San Francisco, CA

Agenda

Agenda

Monday, May 18, 2015

7:00
Registration and Coffee

8:00
Chairperson's Remarks
Jennifer R. Cochran, Ph.D., Associate Professor of Bioengineering and Chemical Engineering, Stanford University

Keynote Presentations

8:15
Peter Senter, Ph.D.
Potent Antibody Drug Conjugates for Cancer Therapy
Peter Senter, Ph.D., Vice President,Chemistry, Seattle Genetics

8:45
Paul J. Carter, Ph.D.
Bispecific Antibodies - Are We There Yet?
Paul J. Carter, Ph.D., Staff Scientist and Senior Director, Antibody Engineering, Genentech, Inc.

9:15
Andreas Plückthun, Ph.D.
New Engineering and Application Perspectives of Scaffold Proteins
Andreas Plückthun, Ph.D., Director, Department of Biochemistry, University of Zurich, Switzerland

9:45
Networking Refreshment Break in Poster and Exhibit Hall

10:10
Chairperson's Remarks
Jennifer R. Cochran, Ph.D., Associate Professor of Bioengineering and Chemical Engineering, Stanford University

Development of Immunotherapies

Featured Presentation

10:15
Karl Dane Wittrup, Ph.D.
Integrin-targeted Cancer Immunotherapy
Karl Dane Wittrup, Ph.D., C.P. Dubbs Professor and Associate Director, Koch Institute at MIT, Massachusetts Institute of Technology

10:45
Manipulation of the Immune Response To Cancer Through Inhibition of the PD-1 Pathway
Gary Starling, Ph.D., Associate Vice President, Biologics Discovery Operations, Merck Research Laboratories

11:15
An Alternative Platform for Fusing Cytokines to Antibodies
Stephen Gillies, Ph.D., Chief Executive Officer and Founder, Provenance Biopharmaceuticals Corp.

11:45
Technology Workshop Presentations

12:15
Networking Luncheon in Poster and Exhibit Hall

1:25
Chairperson's Remarks
Manuel Baca, Ph.D., Fellow, Antibody Discovery and Protein Engineering, MedImmune LLC

Emerging Methods and Technologies for Screening, Selection and Sequencing

1:30
The Role of NGS and In Vitro Selection for Hit Identification and Optimization at BMS
Martin Wright, Ph.D., Associate Director, Selection Technologies, Bristol-Myers Squibb

2:00
Next-Generation Sequencing and Protein Mass Spectrometry for the Comprehensive Analysis of Human Cellular and Serum Antibody Repertoires
Gregory C. Ippolito, Ph.D., Research Assistant Professor, Department of Molecular Biosciences, The University of Texas at Austin

2:30
Applying Deep Sequencing to Antibody Selections
Andrew Bradbury, Ph.D., Research Scientist and Group Leader, Los Alamos National Laboratory

3:00
Networking Refreshment Break in Poster & Exhibit Hall

Disruptive Technologies and Approaches in Protein Discovery, Engineering and Design

3:30
A New Technology Platform that Enables High-Throughput Analysis and Engineering of Antibodies, Biosensors, and Enzymes
Jennifer R. Cochran, Ph.D., Associate Professor of Bioengineering and Chemical Engineering, Stanford University

4:00
Protease-Resistant Human IgGs, Novel Antibodies with Novel Properties for Treatment of Cancers and Infectious Disease Agents
William R. Strohl, Ph.D., Vice President and Head, Biotechnology Center of Excellence, Janssen R&D

4:30
Engineering Albumin to Tailor Half-Life and Improve Efficacy of Protein Drugs
Les Evans, Ph.D., Scientific Manager, Novozymes Biopharma

5:00
Networking Cocktail Reception in Poster and Exhibit Hall

6:00
Dinner Discussions
(Additional registration fee required - see registration page for details)
Please join us for this highly interactive 3 hour evening exchange in a roundtable format, which encourages participants to share their experiences and concerns amongst several discussion topics that include:
  • GPCRs, Ion Channels and Other Membrane Targets - The Next Hot Targets! Why? What are the Challenges?
    Moderator: Catherine Hutchings, Ph.D., Antibody Alliance Management & Strategic Partnering, Heptares Therapeutics Ltd., United Kingdom
  • Delivery Approaches for Intracellular Biologics
    Moderator: Paul Watt, Ph.D., Chief Scientific Officer, Phylogica Ltd., Australia
  • Strategies for Plasma Half-Life Extension of Biopharmaceuticals
    Moderator: Arne Skerra, Ph.D., Professor, Chief Scientific Officer, XL-protein GmbH, Germany
  • Non-Antibody Targeting Moieties
    Moderator: Robert Lutz, Ph.D., Vice President, Translational Research and Development, ImmunoGen, Inc.
  • Clinical Translatability of Current ADC Programs: Does Patient Selection/Tailoring Improve Success
    Moderator: Alan C. Rigby, Ph.D., Vice President, ADC Biology, Eli Lilly and Company
  • Site-Specific Conjugation and its Progress Towards Clinical Development
    Moderator: Jagath Reddy Junutula, Ph.D., Vice President, Antibody Discovery & Development, Cellerant Therapeutics, Inc.
  • CRISPR's Influence on Therapeutic Development
    Moderator: Ben Haley, Ph.D., Scientist, Genentech
  • What Technological Breakthroughs will Make a Difference to Cell line Development: Enthusiasm Tempered by Realism
    Moderator: Alan Dickson, Ph.D., Professor of Biotechnology, Director, Centre of Excellence in Biopharmaceuticals, Co-Director, BioProNET, The University of Manchester, United Kingdom
  • Cell Line Authentication
    Moderator: Leonard P. Freedman, Ph.D., President, Global Biological Standards Institute

Tuesday, May 19, 2015

7:30
Coffee

Track One

8:00
Chairperson's Remarks
Robert Mabry, Ph.D., Associate Director, Antibody Discovery and Bispecific Engineering, Adimab, Inc.

Unlocking New Biology with Novel Scaffolds and Antibody Fragments as Therapeutics

8:15
Adnectins in Engineered, Multi-Component Biologics
Dasa Lipovsek, Ph.D., Senior Principal Scientist, Bristol-Myers Squibb

8:45
Targeted Depletion of Pathogenic T Cells for the Therapy of Chronic Inflammatory Diseases
David Urech, Ph.D., Co-CEO and Chief Scientific Officer, Numab, Switzerland

9:15
In Vitro V(D)J Recombination: A Robust Strategy for Generating Fully Human Agonist and Antagonist Antibodies to GPCRs
Michael Gallo, Ph.D., President, Innovative Targeting Solutions, Inc.

Track Two

8:00
Chairperson's Remarks
Dragan Grabulovski, Ph.D., Chief Scientific Officer, Covagen AG, Switzerland

Novel Therapeutic Peptide Development

8:15
Phylomer Derived Cell Penetrating Peptides Facilitate More Efficient Delivery of Peptides and Proteins to the Cytoplasm
Paul Watt, Ph.D., Chief Scientific Officer, Phylogica Ltd., Australia

8:45
Orally Delivered and Injected Constrained Peptides for Inflammatory Bowel Disease
Mark Smythe, Ph.D., Founder and Vice President, Protagonist Therapeutics

9:15
Discovery and Development of Unnatural Peptide Drugs
Kristopher Josephson, Ph.D., Senior Director, Discovery Research, Ra Pharmaceuticals, Inc.

9:45
Networking Refreshment Break in Poster and Exhibit Hall

Addressing Difficult Targets with Protein Therapeutics

10:30
Venoms to Drugs: Harnessing Disulfide-Rich Peptides from Venomous Animals to Target Neuronal Ion Channels Involved in Human Disease
Glenn F. King, Ph.D., Professor and NHMRC Principal Research Fellow, Institute for Molecular Bioscience, The University of Queensland, Australia

11:00
GPCR Structure Guided Drug Discovery
Catherine Hutchings, Ph.D., Antibody Alliance Management & Strategic Partnering, Heptares Therapeutics Ltd., United Kingdom

Delivery of Proteins

10:30
Creating Biologics that Cross the Blood-Brain Barrier using a Peptide Conjugation Strategy
Jean Lachowicz, Ph.D., Chief Scientific Officer, Angiochem

11:00
Precision Delivery of Biologics into the Cytosol of Cells
Bradley L. Pentelute, Ph.D., Pfizer-Laubach Career Development Professor, Associate Member, Broad Institute of Harvard and MIT, Member, Center for Environmental Health Sciences MIT, Massachusetts Institute of Technology

Plenary Sessions

11:30
Technology Workshop Presentations

12:00
Networking Luncheon in Poster and Exhibit Hall

1:25
Chairperson's Remarks
Dimiter Dimitrov, Ph.D., Senior Investigator, Protein Interactions, National Cancer Institute, NIH

Site-Specific Conjugation Methods and Strategies

1:30
Overcome Key Challenges in Antibody Drug Conjugate Design through the SMARTag Technology Platform
Robyn Barfield, Ph.D., Group Leader, Bioconjugation, Catalent Pharma Solutions

2:00
De-risking ADC Development Through Cell-free Based Rapid Make-test Cycles
Alexander Steiner, M.S., Director, Protein Biochemistry, Sutro

2:30
Site-specific Conjugation Through Carbohydrates
Dimiter Dimitrov, Ph.D., Senior Investigator, Protein Interactions, National Cancer Institute, NIH

3:00
Networking Refreshment Break and Last Chance for Poster and Exhibit Viewing

Next Generation Bioconjugates

Featured Presentation

3:45
Robert Lutz, Ph.D. Clinical Development of ADCs Lessons Learned and Where Do We Go From Here
Robert Lutz, Ph.D., Vice President, Translational Research and Development, ImmunoGen, Inc.

4:15
PEG Alternatives - New Applications of PASylation for Therapeutic Protein Development
Arne Skerra, Ph.D., Professor, Chief Scientific Officer, XL-protein GmbH, Germany

4:45
Close of Tuesday Sessions

5:00
Join Us... Happy Hour @ Pier 39 Overlooking San Francisco Bay
This networking reception is at Players Sports Grill & Arcade, which has sweeping views of San Francisco Bay. Enjoy buffet finger food and drinks (beer, wine, soft drinks) plus arcade games and pool tables. Transportation will be provided. Limited tickets for this event remain for an additional $125 fee. If you want to register for this reception, please stop by the registration desk to reserve your spot.

Wednesday, May 20, 2015

7:30
Coffee

8:00
Chairperson's Remarks
Arne Skerra, Ph.D., Professor, Chief Scientific Officer, XL-protein GmbH, Germany

Keynote Presentations

8:15
Patrick Baeuerle
Development of Bite® Antibody Construct Blinatumomab - The First FDA-Approved Bispecific Antibody
Patrick Baeuerle, Vice President, Research; General Manager, Amgen Research GmbH, Germany

8:45
James A. Wells, Ph.D.
Engineered Proteins for Signaling
Jim Wells, Ph.D., Professor and Chair, Pharmaceutical Chemistry, UCSF

9:15
Mark S. Dennis
Receptor-Mediated Delivery of Bispecific Antibodies into the Primate Brain: Challenges and Safety Findings
Mark Dennis, Ph.D., Principal Scientist, Antibody Engineering, Genentech, Inc.

9:45
Networking Refreshment Break

Bispecific and Multispecifics - New Development Approaches, Design, and Results from the Clinic

10:15
An Open Cell Free Protein Synthesis Platform to Discover Novel Antibodies and Bispecifics
Aaron K. Sato, Ph.D., Vice President, Research, Sutro Biopharma, Inc.

10:45
Tumor-Targeted Drug Delivery Via XTEN™, A Protein-Polymer Offering Precisely Controlled Structure and Valency
Volker Schellenberger, Ph.D., President and CEO, Amunix Operating Inc.

11:15
Engineering Novel Bispecific Antibody/Fusion Protein for Enhanced Biological Activity
Zhenping Zhu, M.D., Ph.D., Executive Vice President, Global Biologics, Kadmon Corporation

11:45
Technology Workshop Presentations

12:15
Lunch on your Own

1:25
Chairperson's Remarks
H. Kaspar Binz, Ph.D., Vice President and Co-Founder, Molecular Partners AG, Switzerland

Bispecific and Multispecifics - New Development Approaches, Design, and Results from the Clinic (continued)

1:30
Closing in Cancer Using Multi-Specific DARPins
Kaspar Binz, Ph.D., Vice President, Protein Engineering and Co-Founder, Molecular Partners AG, Switzerland

2:00
CD3-Folate Bioconjugates for the Treatment of Ovarian Cancer
Olivier Laurent, Ph.D., Vice President, CMC, Ambrx

2:30
Improving the Developability of a Bispecific Scaffold with Protein Design
Steven Jacobs, Ph.D., Associate Scientific Director, Biologics Research, Janssen R&D

3:00
Roundtable Discussions & Networking Refreshment Break

Bispecific and Multispecifics - New Development Approaches, Design, and Results from the Clinic (continued)

3:30
Nanobodies as a Versatile and Clinically Validated Approach for Multi-Specifics
Antonin de Fougerolles, Ph.D., Chief Scientific Officer, Ablynx, Belgium

4:00
Discovery and Characterization of COVA322 - A Clinical-Stage Bispecific TNF/IL-17A Inhibitor
Michela Silacci, Ph.D., Director, Discovery Research, Covagen AG, one of the Janssen Pharmaceutical Companies of J&J, Switzerland

4:30
Engineered Affibody-Based Ligand-Trap that Block IL-17 with Unparalleled In Vivo Potency
Foachim Feldwisch, Ph.D., Director, Preclinical Development, Affibody AB, Sweden

5:00
Close of Conferences